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Monoclonal antibodies have been employed to target therapeutic
agents to tumour cells to increase treatment specificity. The thera-
peutic efficacy of immunoconjugates, however, is limited by their
low uptake (Jain, 1990) and heterogeneous distribution in solid
tumours (Sung et al, 1993). Antigen-negative or inaccessible
tumour cells may escape destruction and repopulate the tumour,
leading to treatment failure.
Many of the limitations associated with conventional immuno-
conjugates may be minimized by antibody-directed enzyme
prodrug therapy (ADEPT), in which prodrugs are enzymatically
converted to antineoplastic agents by enzyme-immunoconjugates
localized at tumour cells (Bagshawe et al, 1988; Senter et al,
1988). Large amounts of antibody-enzyme conjugate can be
administered to maximize tumour uptake as the conjugate is
nontoxic. In addition, an antineoplastic drug is catalytically
produced from a prodrug, allowing accumulation of high drug
concentrations at the tumour site (Wallace et al, 1994) and elimi-
nating the need to link drugs directly to antibodies which can
damage immunoreactivity (Chari et al, 1995). Antineoplastic
drugs generated at antigen-positive tumour cells may also produce
a bystander effect by diffusing to neighbouring antigen-negative
tumour cells as well as to tumour cells that are inaccessible to anti-
body conjugates.
Although a bystander effect is expected to be an important
advantage of ADEPT, only in vitro evidence of bystander killing
by antibody-targeted prodrug activation has been reported (Sahin et
al, 1990; Ejigu Retta et al, 1996). We therefore set out to determine
if the targeted activation of a glucuronide prodrug (BHAMG) of 
p-hydroxyaniline mustard (pHAM) could kill antigen-negative
bystander tumour cells both in vitro and in vivo. The rat hepatoma
cell lines AS-30D and N1S1 were employed in the current study as
antigen-positive and antigen-negative tumour cells, respectively.
bG was linked to Mab RH1 to target this enzyme to AS-30D cells
(Roffler et al, 1994). BHAMG can be preferentially converted to
pHAM at AS-30D cells targeted with RH1-bG (Wang et al, 1992).
Targeted activation of BHAMG with RH1-bG also displayed
potent antitumour activity against malignant ascites in a rat model
(Chen et al, 1997) and against solid rat hepatoma tumours in scid
mice (Cheng et al, 1997). We now report that the targeted activation
of BHAMG produces a bystander effect both in vitro and in vivo.
MATERIALS AND METHODS
The synthesis of pHAM and BHAMG has been described (Roffler
et al, 1991). Bolton-Hunter reagent (125I) was purchased from
Amersham (Buckinghamshire, UK). Succinimidyl succinate
poly(ethylene glycol) MW = 5000 and Sepharose CL-4B protein A
were purchased from Sigma Chemical Company, St. Louis, MO,
USA. Recombinant bG was produced as described (Cheng et al,
1997).
Cell lines
The AS-30D rat hepatoma cell line (Smith et al, 1970) was
provided by Dr JP Chang, Institute of Zoology, Academia Sinica,
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Type Culture Collection (Manassas, VA). Cells were passaged 
as ascites tumours in Sprague–Dawley rats and cultured in
Dulbecco’s modified Eagle’s medium (Gibco BRL, Grand Island,
NY, USA) supplemented with 5% (AS-30D) or 10% (N1S1) heat-
inactivated bovine serum, 100 U ml–1 penicillin and 100 mg ml–1
Streptomycin.
Antibodies
Mab RH1, an IgG2a monoclonal antibody specific for AS-30D rat
hepatoma cells, has been described (Roffler et al, 1994).
Hybridoma H16-L10-4R, which secretes a murine IgG2a antibody
(Mab HB65) against the nucleoprotein of influenza type A viruses,
was obtained from the American Type Culture Collection. Mabs
were purified by protein-A affinity chromatography from ascites
produced in BALB/c mice. FITC and horseradish peroxidase-
conjugated antibodies were from Organon Teknika (Turnhout,
Belgium) or Dako (Kyoto, Japan).
Animals
BALB/c mice were obtained from the animal room of the Institute
of Biomedical Sciences, Academia Sinica. BALB/c nu/nu mice
were from the National Laboratory Animal Breeding and Research
Center, National Science Council, Taipei. Animal experiments
were performed in accordance with institute guidelines.
Antibody–enzyme conjugates
Recombinant bG derived from Escherichia coli was modified with
an average of three molecules of methoxy polyethylene glycol
(5000 kDa) as described (Cheng et al, 1997) to decrease non-
specific binding and extend the serum half-life of the conjugates.
PEG modification can also decrease the antigenicity and immuno-
genicity of bG (manuscript in preparation). PEG-modified bG was
linked to Mab RH1 and Mab HB65 by a thioether linkage (Wang et
al, 1992) to produce the conjugates RH1-bG-PEG and HB65-bG-
PEG. The antigen-binding and enzymatic activities of these conju-
gates have been reported (Cheng et al, 1997).
Membrane immunofluorescence
AS-30D and N1S1 cells were incubated for 1 h at 4°C in 
500  mL PBS containing 67 nM Mab or conjugate. The cells were
washed twice, incubated 1 h on ice with FITC conjugated goat
anti-mouse IgG (Organon Teknika, 1:500) and washed again
before the surface immunofluorescence of 10 000 cells was
measured with a FACSCalibur flow cytometer (Becton Dickinson,
Mountain View, CA, USA). Mean fluorescent intensities were
estimated with the Cell Quest software (Becton Dickinson).
Background fluorescence was determined by omitting the first
antibody before incubation with FITC conjugate.
In vitro cytotoxicity
AS-30D or N1S1 cells (106) were suspended in 500 ml of medium
containing various concentrations of pHAM or BHAMG for 2 h at
37°C. Cells were then transferred to 6-well plates and cultured in 
5 ml medium for 4 days before viable cell numbers in each well
were determined by trypan blue exclusion. DMSO, used to
dissolve pHAM, was not toxic to AS-30D and N1S1 cells at the
maximum final concentrations employed (0.125%). Experiments
were carried out in quadruplicate.
In vitro bystander assay
AS-30D, N1S1 or mixtures of AS-30D and N1S1 cells were
suspended in 500 ml of medium. RH1-bG-PEG (10 mg ml–1 final
concentration) or PBS were added for 30 min before washing the
cells three times with PBS. Cells were suspended in 500 ml of
medium or medium containing 20 mM BHAMG or 20 mM pHAM
for 2 h at 37°C. Cells were then quantitatively transferred to 6-well
culture plates in 5 ml fresh medium and cultured for 4 days before
viable cell numbers were determined by trypan blue exclusion.
Cultures containing both AS-30D and N1S1 cells were incubated
with 20 mg ml–1 Mab RH1 at 4°C for 1 h, washed twice with PBS,
and suspended in PBS containing FITC conjugated goat anti-
mouse IgG (1:500) for 30 min. Cells were washed once with PBS
before examination of four to 10 fields under visible light as well
as under UV illumination with a fluorescent filter to differentiate
AS-30D and N1S1 cells. The ratio of AS-30D to N1S1 cells along
with the total number of viable cells determined by trypan blue
exclusion were used to calculate the number of each cell type
present in mixed cultures. Results represent the mean values of
four determinations.
Immunohistochemical staining
Mice were s.c. injected in the right flank with AS-30D cells, N1S1
cells, or mixed AS-30D/N1S1 cells. Tumours were excised after
they grew to 200–300 mm3, embedded in O.C.T. compound (Miles
Inc., Elkhart, NJ, USA) and snap frozen. Thin sections were incu-
bated with 3 mg ml–1 Mab RH1 or Mab HB65 in PBS at 4°C
overnight and then sequentially incubated with biotin-labelled
rabbit anti-mouse Ig (Dako) and streptavidin-conjugated horse-
radish peroxidase (Dako) diluted 1:500 in PBS. Binding was visu-
alized with 3,3¢-diaminobenzidine before viewing under a light
microscope.
Radiolabelling of conjugates
RH1-bG-PEG and HB65-bG-PEG were labelled with 125I
Bolton–Hunter reagent to specific activities of 0.73 and 
0.72 mCi mg–1, respectively, according to the manufacturer’s
instructions. Conjugates retained antigen-binding activity and
specificity as determined by radioimmunoassay against AS-30D
and N1S1 cells coated in 96-well microtitre plates. bG activity was
unaffected and conjugates were not degraded as determined by
autoradiography of gels after sodium dodecyl sulphate polyacry-
lamide electrophoresis.
Tumour localization of radiolabelled conjugates
Eighteen BALB/c nu/nu mice were injected s.c. with 5 ´ 106 AS-
30D cells in the left flank, 7.5 ´ 106 N1S1 cells in the right flank
and 107 mixed AS-30D/N1S1 (1:1) cells in the right shoulder.
When tumours grew to between 50 and 200 mm3, mice were i.v.
injected with 200 mg [125I]RH1-BG-PEG or [125I]HB65-bG-PEG.
Groups of three mice were killed and dissected after 72, 96 and
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120 h. Tumours, blood and organs were weighed on an analytical
balance and assayed for radioactivity in a multichannel g-counter.
Results are expressed as specific uptake of conjugate in tumour or
tissue (cpm mg–1) and as localization index, defined as the ratio of
specific (RH1-bG-PEG) to nonspecific (HB65-bG-PEG) conju-
gate uptake in tumour or tissue, normalized to the radioactivity in
the blood of mice. Localization index (LI) was calculated by:
Localization index =
(cpm mg–1 tissue/cpm mg–1 blood) RH1-bG-PEG
(cpm mg–1 tissue/cpm mg–1 blood) HB65-bG-PEG.
Toxicity of prodrug activation by circulating conjugate
Twenty BALB/c mice were i.v. injected with 300 mg RH1-bG-
PEG on day 1. Groups of 5 mice were then i.v. injected with 
15 mg kg–1 BHAMG 72, 96, 120 or 144 h later. The number of
white blood cells, red blood cells, and platelets in blood samples
collected from the lateral tail vein of mice 1 day before and 9 days
after BHAMG treatment were determined as described (Cheng et
al, 1997).
In vivo bystander killing
Groups of 14 BALB/c nu/nu mice were s.c. injected in the right
flank with 3 ´ 106 AS-30D cells, 3 ´ 106 N1S1 cells or a mixture of
1.5 ´ 106 AS-30D and 1.5 ´ 106 N1S1 cells on day 1. On day 4, the
mice in each group were i.v. injected with either 300 mg RH1-bG-
PEG or HB65-bG-PEG followed 5 days later by two i.v. injections
(3 h delay) of 15 mg kg–1 BHAMG dissolved in PBS. Mice were
administered a second round of therapy on day 16 consisting of
200 mg conjugate followed 5 days later with 2 doses of 10 mg kg–1
BHAMG. Mouse weight and tumour dimensions were measured
biweekly. Tumour volumes were estimated by 0.5 ´ (length  ´
height ´ width).
Statistical analysis
Statistical significance of differences between mean values was
estimated with the shareware program Schoolstat (White Ant
Occasional Publishing, West Melbourne, Australia) using the inde-
pendent t-test for unequal variances.
RESULTS
Characterization of the bystander model
AS-30D rat hepatoma cells were used as antigen-positive tumour
cells to examine whether the targeted activation of BHAMG could
generate a bystander effect. These cells express a 32 kDa surface
antigen that can be targeted with Mab RH1 (Roffler et al, 1994).
N1S1 rat hepatoma cells, employed as antigen-negative cells, grew
in vitro with a doubling time of 15 h. AS-30D cells grew slightly
slower with a doubling time of 19.4 h. Mab RH1 and control Mab
HB65 were linked to bG that had been modified with an average
of three molecules of methoxy poly(ethylene glycol) to form the
conjugates RH1-bG-PEG and HB65-bG-PEG. Table 1 summar-
izes the binding characteristics of the antibodies and conjugates to
AS-30D and N1S1 cells as determined by indirect immunofluores-
cence and flow cytometric analysis. Mab RH1 and RH1-bG-PEG
preferentially bound to AS-30D cells; about 110 times more RH1
and 145 times more RH1-bG-PEG bound to AS-30D cells than to
N1S1 cells. RH1-bG-PEG did not specifically bind N1S1 cells as
shown by the similar mean fluorescence values of RH1-bG-PEG
and HB65-bG-PEG for these cells. N1S1 tumour cells are thus
considered to be ‘antigen-negative’ in the present study. The
control antibody conjugate, HB65-bG-PEG, did not specifically
bind to AS-30D or N1S1 cells (Table 1).
BHAMG was relatively nontoxic to both AS-30D and N1S1
cells with IC50 values of 130 and > 200 mM, respectively (Figure
1). pHAM, on the other hand, was over 250 times more toxic with
IC50 values of 0.2 and 0.8 mM for AS-30D and N1S1 cells, respec-
tively. AS-30D cells were more sensitive than N1S1 cells to
pHAM at low concentrations (< 2 mM) but slightly less sensitive at
higher drug concentrations.
In vitro bystander killing
Bystander killing was first examined in cultures containing equal
numbers of AS-30D and N1S1 cells. Figure 2 shows that addition
of 20 mM pHAM to AS-30D or N1S1 cells resulted in over 99%
cell killing. Over 98% of N1S1 and AS-30D cells in a mixed cell
culture were also killed by 20 mM pHAM. BHAMG (20 mM), on
the other hand, was non toxic to both AS-30D and N1S1 cells,
regardless of whether the cells were cultured separately or
together. Incubation of AS-30D cells with RH1-bG-PEG followed
by exposure to BHAMG resulted in the killing of over 99% of
Table 1 Mab and conjugate specificity. AS-30D and N1S1 cells were incubated with Mab RH1, Mab HB65, RH1-bG-PEG, or HB65-bG-PEG and FITC
conjugated goat anti-mouse IgG before 1 ´ 104 cells were analysed for membrane immunofluorescence on a Becton Dickinson FACStar
Antibody or AS-30D cell N1S1 cell AS-30D/N1S1 AS-30D cell N1S1 cell
conjugate fluorescent indexa fluorescent index fluorescent ratiob specific indexc specific index
Mab RH1 1320 12.0 110 185 4.8
RH1-bG-PEG 540 3.7 146 225 1.4
Mab HB65 7.2 2.5 2.8 1.0 1.0
HB65-bG-PEG 2.4 2.7 0.9 1.0 1.0
aThe fluorescent index is the ratio of the mean fluorescence of a Mab or conjugate to the mean background fluorescence (no first antibody or conjugate). bThe
fluorescent ratio is the ratio of the AS-30D to N1S1 fluorescent index for a particular antibody or conjugate. cThe specific index is the ratio of the fluorescent
index of Mab RH1 or RH1-bG-PEG to the fluorescent index of Mab HB65 or HB65-bG-PEG, respectively.Bystander killing by glucuronide prodrugs 1381
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these Ag+ cells. N1S1 cells treated in an identical fashion were
resistant to the glucuronide prodrug, indicating that these cells
were unable to bind RH1-bG-PEG and activate BHAMG.
Incubation of a mixture of AS-30D and N1S1 cells with RH1-bG-
PEG, in contrast, produced a strong bystander effect upon addition
of BHAMG with over 98% killing of both Ag+ and Ag– tumour
cells.
The potency of the bystander effect was examined by
performing mixing experiments with different ratios of AS-30D
and N1S1 cells. Figure 3 shows that a strong bystander effect was
observed after sequential treatment of cells with RH1-bG-PEG
and BHAMG in cell populations containing as few as 2% AS-30D
cells. The slightly greater killing of N1S1 cells compared with
AS-30D cells in mixed cultures can be attributed to the greater
sensitivity of N1S1 cells to pHAM concentrations greater than
2 mM.
Immunohistochemical staining of tumour xenografts
Athymic mice were employed for animal studies to minimize the
possibility of immune-mediated bystander killing of tumour cells
because we have shown that rats cured of hepatoma ascites by
combined treatment with RH1-bG and BHAMG were completely
protected from a lethal challenge of AS-30D cells (Chen et al,
1997). The ability of mixed AS-30D and N1S1 tumour xeno-
grafts to grow in BALB/c nu/nu mice was first assessed.
Immunohistochemical staining of tumour sections showed that
Mab RH1 uniformly stained AS-30D tumours (Figure 4A) but
did not bind to N1S1 tumour sections (Figure 4B). Mixed AS-
30D/N1S1 tumours exhibited areas of strong staining with Mab
RH1 (Figure 4C), demonstrating the presence of AS-30D cells
in mixed tumours. Unstained tumour cells were evident after light
haematoxylin staining (Figure 4D), indicating that mixed tumours
also contained N1S1 cells. AS-30D and N1S1 cells in mixed
tumours were nonrandomly distributed with some segregation of
the two cell lines (Figure 4D). Mab HB65 did not stain either
AS-30D or N1S1 cells (data not shown). AS-30D, N1S1 and
mixed AS-30D/N1S1 tumours grew at equivalent rates until
tumours reached approximately 200 mm3 at which time N1S1
tumours grew about 25% slower (data not shown).
Tumour localization of RH1-bG-PEG
The distribution of radiolabelled conjugates in tumour-bearing
mice was examined to determine whether RH1-bG-PEG specifi-
cally localized in mixed tumours. AS-30D tumours accumulated
higher levels of radioactivity compared with normal tissues after
i.v. injection of RH1-bG-PEG at all times examined (Figure 5A).
RH1-bG-PEG cleared from blood and normal tissues faster than
from AS-30D tumours, resulting in progressively higher
tumour/tissue ratios from 72 to 120 h. For example, AS-
30D/tissue ratios at 120 h ranged from 5.0 ± 0.4 for blood to 28 ±
4.7 for the intestine. Figure 5A shows that RH1-bG-PEG also
localized in mixed AS-30D/N1S1 tumours, although specific
uptake was about 25% lower than in AS-30D tumours after 120 h
(432 vs 318 cpm mg–1). HB65-bG-PEG did not localize in any of
the tumours (Figure 5B). Calculation of the localization index
(Table 2), the ratio of RH1-bG-PEG to HB65-bG-PEG uptake
normalized for the serum concentration of the conjugates, indi-
cated selective uptake of RH1-bG-PEG by AS-30D and mixed
AS-30D/N1S1 tumours; there was 11.6 times more RH1-bG-PEG
than HB65-bG-PEG in AS-30D tumours 120 h after conjugate
administration, whereas mixed AS-30D/N1S1 tumours bound
over nine times more specific conjugate than HB65-bG-PEG after
120 h. In contrast, the localization index of most tissues was near
unity, indicating equal uptake of specific and control conjugates.
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Figure 1 Sensitivity of tumour cells to pHAM and BHAMG. The viability of
AS-30D (squares) or N1S1 (circles) cells were determined 4 days after the
cells were exposed to pHAM (open symbols) or BHAMG (solid symbols) for
2 h at 37°C. Results represents the mean viability of cells (n = 4) compared
with untreated cells, bars = SE
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Figure 2 In vitro bystander killing of antigen-negative cells. Separate or
mixed groups containing equal numbers of AS-30D and N1S1 cells were
incubated with RH1-bG-PEG or culture medium for 30 min. After washing,
cells treated with RH1-bG-PEG were exposed to BHAMG whereas the other
groups were treated with pHAM, BHAMG, or medium alone for 2 h. Results
show the mean survival of treated cells relative to untreated cells determined
4 days later, bars = SE1382 TL Cheng et al
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The N1S1 tumour localization index was near unity after 72 and
96 h, showing that RH1-bG-PEG did not specifically accumulate
in N1S1 tumours at these times. The N1S1 index of 2 at 120 h can
be attributed to higher serum concentrations of HB65-bG-PEG
(Figure 5B) relative to RH1-bG-PEG (Figure 5A). The N1S1
localization index was not significantly higher than any normal
tissue except for the intestine after 120 h.
In vivo bystander effect
Conversion of BHAMG to pHAM by RH1-bG-PEG present in the
circulation could produce systemic toxicity and decrease the thera-
peutic index of treatment. A single i.v. injection of 15 mg kg–1
BHAMG did not decrease white blood cell numbers or animal
weight as long as the concentration of RH1-bG-PEG in serum was
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Figure 3 Potency of in vitro bystander killing. Mixed populations containing different ratios of cells (AS-30D:N1S1) were treated as described in Figure 2.
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Figure 4 Immunohistochemical staining of tumour xenografts. Thin sections of AS-30D (A), N1S1 (B) and mixed AS-30D/N1S1 (C, D) tumours were
incubated with Mab RH1. Tissue sections were subsequently incubated with biotin-labelled goat anti-mouse Ig and streptavidin-conjugated horseradish
peroxidase before addition of substrate. Magnification: A, ´ 200; B ´ 400; C ´ 400; D, ´ 100. The section in panel D was counterstained with haematoxylinBystander killing by glucuronide prodrugs 1383
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Figure 5 Biodistribution of [125I]labelled conjugates in tumour-bearing BALB/c nu/nu mice. Radioactivity of tumours and tissues were determined 72, 96 and
120 h after nude mice bearing AS-30D, N1S1, and mixed AS-30D/N1S1 tumours were i.v. injected with 200 mg RH1-bG-PEG (A) or HB65-bG-PEG (B). Results
represent the mean values of three mice, bars = SE
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Figure 6 In vivo bystander effect. Groups of seven BALB/c nu/nu mice bearing AS-30D (n n), N1S1 (s s) or mixed AS-30D/N1S1 (1:1 ratio) (l l) tumours were i.v.
injected with RH1-bG-PEG (open symbols) or HB65-bG-PEG (solid symbols) on day 4 followed by two i.v. injections of BHAMG on day 9. Mice were again i.v.
injected with conjugates on day 16 and BHAMG on day 21. Mean tumour volumes of each group are shown. Bars = SE of the mean. The mean size of AS-30D
and mixed AS-30D/N1S1 tumours in mice treated with BHAMG and RH1-bG-PEG were significantly (P ≤ 0.01) smaller than the corresponding tumours in mice
treated with BHAMG and HB65-bG-PEG after day 131384 TL Cheng et al
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less than about 3 mg ml–1. The concentration of RH1-bG-PEG was
7.3 ± 0.7 mg ml–1 4 days and 1.4 ± 0.9 mg ml–1 5 days after i.v.
injection of 300 mg ml–1 conjugate indicating that a minimum
delay of 5 days between RH1-bG-PEG and BHAMG administra-
tion would be appropriate for in vivo therapy of solid tumours.
Bystander killing was examined in nude mice which were
xenografted with equal numbers of AS-30D and N1S1 cells. Mice
were i.v. injected with RH1-bG-PEG or HB65-bG-PEG on day 4
and BHAMG on day 9. All mice received a second round of
therapy consisting of i.v. injections of conjugate on day 16 and
prodrug on day 21. Figure 6 shows that treatment of mice bearing
AS-30D tumours with RH1-bG-PEG and BHAMG resulted in
complete tumour regressions in seven of seven mice with all mice
appearing tumour-free on day 90. Treatment of mixed AS-
30D/N1S1 tumors with RH1-bG-PEG and BHAMG significantly
(P ≤ 0.01 after day 13) suppressed tumour growth compared with
mixed tumours which were treated with control conjugate and
BHAMG. For example, the mean size of mixed tumours treated
with RH1-bG-PEG was 51 mm3 vs 1390 mm3 for mice treated
with HB65-bG-PEG on day 29. Furthermore, one of seven mice
bearing mixed AS-30D/N1S1 tumours was cured by treatment
with RH1-bG-PEG (no evidence of a tumour on day 90).
Treatment was specific as shown by the lack of efficacy against
N1S1 tumours regardless of whether mice were treated with
RH1-bG-PEG or HB65-bG-PEG in combination with BHAMG.
Immunohistochemical staining of frozen sections prepared from
mixed tumours treated with RH1-bG-PEG and BHAMG which
were recovered on day 55 revealed that viable AS-30D cells were
still present (20% of N1S1 cells), indicating selective killing of
antigen-positive tumour cells.
DISCUSSION
The bystander effect produced by the targeted activation of
BHAMG was examined in a model employing AS-30D and N1S1
rat hepatoma cell lines. This model was chosen for several reasons:
(1) AS-30D cells express a 32 kDa antigen (Roffler et al, 1994)
which can be targeted with RH1-bG-PEG, whereas immunofluo-
rescence and histochemical staining of tumours demonstrated that
this conjugate did not bind to N1S1 cells; (2) the targeted activa-
tion of BHAMG has been shown to exibit antitumour activity
against AS-30D tumours. Combined treatment with RH1-bG and
BHAMG cured 75% to 100% of rats bearing advanced AS-30D
ascites (Chen et al, 1997), while treatment with RH1-bG-PEG and
BHAMG cured 100% of mice bearing small solid AS-30D
tumours (Cheng et al, 1997). pHAM did not exhibit significant
antitumour activity in either model. (3) AS-30D and N1S1 cells
displayed similar growth rates and drug sensitivities to pHAM. (4)
AS-30D and N1S1 were able to form mixed tumours in nude mice
as demonstrated by immunohistochemical staining of tumour
sections. Nude mice were employed in this study to eliminate
possible immunological-mediated bystander killing of mixed
tumours because combined treatment of AS-30D ascites with
RH1-bG and BHAMG was shown to induce protective immunity
in rats (Chen et al, 1997).
Experiments employing different ratios of AS-30D and N1S1 cells
showed that substantial killing of antigen-negative cells was
achieved when up to 98% of the cell population contained
Ag– tumour cells. The magnitude of the in vitro bystander effect
generated by the targeted activation of BHAMG appears to be at least
as great as the bystander effect produced by other enzyme/prodrug
combinations. For example, activation of a phosphate prodrug of
Mitomycin C by alkaline phosphatase localized at CD30-positive
cells by a bispecific antibody produced less cytotoxicity to CD30-
negative cells than Mitomycin C in cultures containing equal
numbers of Ag+ and Ag– cells (Sahin et al, 1990). Activation of a
phenol mustard prodrug by an antibody-carboxypeptidase G2 conju-
gate at CEA-positive LS174T colon adenocarcinoma cells produced
a strong bystander effect at non CEA-producing lung carcinoma cells
in cultures containing equal cell numbers, although the IC50 value
was about double the value determined for the parent drug (Ejigu
Retta et al, 1996). The extent of the bystander effect produced
by other enzyme/prodrugs containing different ratios of Ag+ and
Ag– tumour cells has not been reported.
The targeted activation of BHAMG also produced bystander
killing of antigen-negative tumour cells in vivo. This was clearly
demonstrated by the large difference in the size of mixed
AS-30D/N1S1 tumours treated with RH1-bG-PEG or HB65-bG-
PEG and BHAMG (51 mm3 vs 1390 mm3, repectively, on day 29).
The suppression of mixed AS-30D/N1S1 tumours cannot be
ascribed to killing of only the AS-30D cells because the mixed
tumours were much smaller than N1S1 tumours treated with
RH1-bG-PEG and BHAMG (72 vs 1340 mm3 on day 42). Mixed
tumours contained viable AS-30D cells 5 weeks after the last
round of prodrug treatment, suggesting that further tumour
suppression could be achieved by repeated treatment. A bystander
effect was also probably important for the cure of AS-30D
tumours, as it is unlikely that RH1-bG-PEG reached every cancer
cell given the extremely heterogeneous distribution of RH1-bG in
malignant ascites even after direct injection of conjugate into the
peritoneal cavity (Chen et al, 1997).
Table 2 In vivo distribution of [125I]RH1-bG-PEG compared to [125I]HB65-bG-
PEG. The mean radioactivity of tissues taken from groups of three athymic
mice bearing AS-30D, N1S1 and mixed AS-30D/N1S1 tumour xenografts at
the indicated times after i.v. injection of 140 mCi [125I]RH1-bG-PEG or
[125I]HB65-bG-PEG are shown
Localization indexa
Tissue 72 h 96 h 120 h
Blood 1.00 1.00 1.00
AS-30D 3.87 ± 0.39 5.55 ± 1.18 11.63 ± 1.88
AS-30D/N1S1 3.79 ± 0.14 3.79 ± 0.90 9.26 ± 0.81
N1S1 1.11 ± 0.18b,cc 1.22 ± 0.22b 2.05 ± 0.34b,cc
Liver 0.80 ± 0.14b,cc 0.95 ± 0.11b,c 1.21 ± 0.13b,cc
Lung 0.87 ± 0.05b,cc 1.30 ± 0.43b,c 1.13 ± 0.13b,cc
Kidney 0.81 ± 0.08b,cc 0.86 ± 0.11b,c 1.35 ± 0.61b,cc
Spleen 1.12 ± 0.55b,c 1.11 ± 0.17b,c 1.25 ± 0.13b,cc
Intestine 1.31 ± 0.24b,cc 1.11 ± 0.10b,c 0.85 ± 0.17b,cc,d
Colon 0.95 ± 0.47b,c 1.13 ± 0.05b,c 1.82 ± 0.87b,cc
aLocalization index represents a normalized ratio of RH1-bG-PEG binding
compared with HB65-bG-PEG binding in tissues and was calculated as
described in Materials and Methods. Results represent the mean ratios ± SE
obtained using three mice for each conjugate. Significant differences
between AS-30D (bP ≤ 0.05), mixed AS-30D/N1S1 (cP ≤ 0.05; ccP ≤ 0.005) or
N1S1 tumour xenografts (dP ≤ 0.05) and other tissues is indicated.Bystander killing by glucuronide prodrugs 1385
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The bystander effect produced by the targeted activation of
BHAMG may help to mitigate the impact of heterogeneous
immunoconjugate distribution in tumours. Immunoconjugates are
large molecules with molecular weights typically ranging from 60
kDa to more than 200 kDa. Although blood vessels in tumours are
‘leaky’ (Tomlinson, 1990) and have increased permeability
compared with normal tissues (Gerlowski and Jain, 1986), the
convection of immunoconjugates into the interstitial space around
cancer cells is hindered by the elevated pressures in solid tumours
(Less et al, 1992). Antibody uptake therefore ranges from only
0.0006 to 0.02% of the total injected dose per gram of tumour in
humans (Douillard et al, 1986; Rosenblum et al, 1991).
Immunoconjugate distribution in tumours is also highly heteroge-
neous due to variable antigen expression and uneven perfusion of
blood to different regions of the tumour (Shockley et al, 1992).
Immunoconjugate penetration into tumours is also hindered by
specific binding of antibody to antigens expressed on tumour cells
near blood vessels (Fujimori et al, 1990). In contrast to immuno-
conjugates, diffusion of low molecular weight drugs is relatively
efficient. For example, pHAM is estimated to diffuse over 370
times faster than IgG (Baxter et al, 1992), suggesting that
bystander cells may be reached by both convection and diffusion.
Our results thus show that the targeted activation of BHAMG
produced a bystander effect in vitro and in vivo. This therapeutic
strategy may benefit the treatment of tumours that display hetero-
geneous immunoconjugate uptake.
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